According to the Acumen Research, “The global Gene Editing Market Size is projected to reach USD 9.2 billion by 2026, growing with a CAGR between 15.3% from 2020 to 2026”. The market report provides an analysis of the global Gene Editing Market for the period 2016-2026, wherein 2020 to 2026 is the forecast period and 2019 is considered as the base year.

An increase in demand for synthetic genes in the North America and Asia Pacific regions and growing funding for genetic research in developed as well as developing countries will boost the gene editing market in the coming years.

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa are the major regions. Currently, North America holds the largest share of the global gene editing market and is anticipated to maintain its position during the forecast period. This can be attributed to the local presence of major market players, early adoption of the latest technology of gene editing, and higher awareness about benefits associated with gene editing. Furthermore, high government funding and investments by market players for research and development activities on genetic modification further boost the market. The Asia Pacific is expected to grow at a steady rate due to the slow adoption of technology and an unorganized regulatory environment across and within countries. However, government funding, an increasing number of laboratories, and investment by market players are expected to propel the market growth. China dominates the market due to high penetration and more research. Patent applications from China for CRISPR have climbed rapidly in the last few years, and hence the country dominates in the industrial and agricultural fields.

Based on technology, the market has been segmented into Clustered regularly interspaced short palindromic repeats (CRISPR), Transcription activator-like effector nuclease (TALEN), Zinc Finger Nuclease (ZFN), and other technologies. CRISPR accounted for the largest share of the market due to a wide range of advantages such as availability of tailor-made option specific to the patient’s mutations for the disease like cystic fibrosis, government initiatives for the development of drug, devices, and vaccines, and investment by market players. For instance, in October 2017, Thermo Fisher Scientific and Synthego collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering. Furthermore, CRISPR is easy to use, works with high throughput, and affordable technology.

Get FREE SAMPLE PDF (Including Full TOC, Table & Figures)@ www.acumenresearchandconsulting.com/request-sample/1769

Based on the application, the global gene editing market is divided into cell line editing, animal genome editing, plant genome editing, and others. In 2018, the animal genetic engineering segment accounted for the largest share of the market. Extensive use of gene-editing technology for altering the animal genome sequence to obtain maximum output from domestic animals is a key factor for the dominance of the segment.

Based on the end-users, the market has been segmented into pharmaceutical & biotechnology companies, academics and government research institutes, and Clinical Research Organizations (CRO). Pharma and biotech companies dominated the market in 2018 and are expected to maintain their dominance during the forecast period. The increasing number of rare diseases and patients and growing investment by pharma and biotech companies to develop new drugs against these rare diseases are the key driving factors of the segment.

Key players operating in the gene editing market are Addgene, Allele Biotech, Bio-Rad, Caribou Biosciences, Inc., CRISPR Therapeutics, Dharmacon Inc., GE Healthcare, GeneCopoeia, Inc., GenScript Corporation, Horizon Discovery Group plc, Integrated DNA Technologies, OriGene Technologies, Merck Millipore Limited, Precision Biosciences, Sangamo Biosciences, Inc., Takara Bio, Agilent Technologies, Inc., and Thermo Fisher Scientific.

Some of the key observations regarding the gene editing industry include:

  • In January 2020, Horizon Discovery Group Plc announced the development of a novel base editing technology licensed from Rutgers, The State University of New Jersey, for diagnostic, therapeutic, and services applications. The company’s new generation base editing is a novel technology for engineering DNA in cells, which can correct certain mutations or errors in the DNA, or inactivate disease-causing genes. Conventional CRISPR/Cas9 technology creates “cuts” in the gene that can lead to adverse or negative effects on patients. However, this newly developed technology allows accurate gene editing while reducing unintended genomic changes.
  • In June 2019, Vertex Pharmaceuticals acquired Exonics Therapeutics for to expand its presence in gene editing. Exonics has its SingleCut CRISPR gene editing technology to develop treatments through repairing mutations that cause DMD and other genetic neuromuscular diseases with significant unmet needs. Hence, the acquisition helps Vertex to develop new treatments against rare diseases.
  • In April 2019, the first time two patients treated by using the CRISPR technique in the U.S. The clinical trial of CRISPR to treat cancer had started. One patient had multiple myeloma, and the other patient had sarcoma. Both had relapsed after undergoing standard treatment. Similarly, other studies are also set to start in the U.S., Canada, and European countries.
  • In January 2019, Horizon Discovery signed a partnership agreement with Rutgers University to commercialize a new gene editing technology. The basic technology was developed in the lab of Rutgers’ Robert Wood Johnson Medical School; however, Horizon through this agreement Horizon will further augment the research and commercialization activities.
  • In December 2015, Bayer signed a partnership agreement for gene editing with CRISPR Therapeutics, a Switzerland based biotech firm. Through this partnership, Bayer will financially support the research activities for the next five years.

Market Segmentation as below:

Market By Technology

  • CRISPR
  • TALEN
  • ZFN
  • Other technologies

By Application

  • Cell line editing
  • Animal genome editing
  • Plant genome editing
  • Others

By End-user

  • Pharmaceutical & biotechnology companies
  • Academics and government research institutes
  • Clinical Research Organizations (CRO)

Market By Geography

(Regional Output, Demand & Forecast by Countries)

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Spain and Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific)
  • Latin America (Mexico, Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, South Africa and Rest of MEA).

FYI, You will get the latest updated report as per the COVID-19 impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Customized Requirements? Inquiry Before Buying? Please Email us at [email protected] | Single User License US$ 4500

Overview of the Impact of COVID-19 on this market:

The development of COVID-19 has carried the world to a stop. We comprehend that this health emergency has brought an unprecedented effect on businesses across ventures. However, this also will pass. Rising help from governments and a few organizations can help in the battle against this profoundly infectious sickness. There are a few industries that are battling and some are flourishing. In general, pretty much every segment is foreseen to be affected by the pandemic.

We are taking persistent efforts to enable your business to continue and develop during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across ventures to assist you to prepare for the future.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Gene Editing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Gene Editing Market By Technology
1.2.2.1. Global Gene Editing Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Gene Editing Market Revenue Share By Technology in 2018
1.2.2.3. CRISPR
1.2.2.4. TALEN
1.2.2.5. ZFN
1.2.2.6. Other technologies
1.2.3. Gene Editing Market By Application
1.2.3.1. Global Gene Editing Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Cell line editing
1.2.3.3. Animal genome editing
1.2.3.4. Plant genome editing
1.2.3.5. Others
1.2.4. Gene Editing Market By End-user
1.2.4.1. Global Gene Editing Market Revenue and Growth Rate Comparison By End-user (2015-2026)
1.2.4.2. Pharmaceutical & biotechnology companies
1.2.4.3. Academics and government research institutes
1.2.4.4. Clinical Research Organizations (CRO)
1.2.5. Gene Editing Market By Geography
1.2.5.1. Global Gene Editing Market Revenue and Growth Rate Comparison By Geography (2015-2026)
1.2.5.2. North America Gene Editing Market Revenue and Growth Rate(2015-2026)
1.2.5.3. Europe Gene Editing Market Revenue and Growth Rate(2015-2026)
1.2.5.4. Asia-Pacific Gene Editing Market Revenue and Growth Rate(2015-2026)
1.2.5.5. Latin America Gene Editing Market Revenue and Growth Rate(2015-2026)
1.2.5.6. Middle East and Africa (MEA) Gene Editing Market Revenue and Growth Rate(2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Gene Editing Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Gene Editing Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Gene Editing Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Gene Editing Major Manufacturers in 2018

CHAPTER 4. GENE EDITING MARKET BY TECHNOLOGY
4.1. Global Gene Editing Revenue By Technology
4.2. CRISPR
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. TALEN
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. ZFN
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Other technologies
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. GENE EDITING MARKET BY APPLICATION
5.1. Global Gene Editing Revenue By Application
5.2. Cell line editing
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Animal genome editing
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Plant genome editing
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. GENE EDITING MARKET BY END-USER
6.1. Global Gene Editing Revenue By End-user
6.2. Pharmaceutical & biotechnology companies
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Academics and government research institutes
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Clinical Research Organizations (CRO)
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. NORTH AMERICA GENE EDITING MARKET BY COUNTRY
7.1. North America Gene Editing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. North America Gene Editing Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Gene Editing Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 8. EUROPE GENE EDITING MARKET BY COUNTRY
8.1. Europe Gene Editing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Europe Gene Editing Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC GENE EDITING MARKET BY COUNTRY
9.1. Asia-Pacific Gene Editing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Asia-Pacific Gene Editing Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 10. LATIN AMERICA GENE EDITING MARKET BY COUNTRY
10.1. Latin America Gene Editing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Latin America Gene Editing Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA GENE EDITING MARKET BY COUNTRY
11.1. Middle East & Africa Gene Editing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Middle East & Africa Gene Editing Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.5. Rest of Middle East & Africa
11.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 12. COMPANY PROFILE
12.1. Addgene
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Type Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Allele Biotech
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Type Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Bio-Rad
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Type Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Caribou Biosciences, Inc.
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Type Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. CRISPR Therapeutics
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Type Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Dharmacon Inc.
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Type Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. GE Healthcare
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Type Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. GeneCopoeia, Inc.
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Type Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. GenScript Corporation
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Type Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Horizon Discovery Group plc
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Type Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Integrated DNA Technologies
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Type Portfolio
12.11.5. Key Developments
12.11.6. Strategies
12.12. Others
12.12.1. Company Snapshot
12.12.2. Overview
12.12.3. Financial Overview
12.12.4. Type Portfolio
12.12.5. Key Developments
12.12.6. Strategies

CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

The Final Report will cover the impact analysis of COVID-19, Download Full Study Report (Single User License US$ 4500)www.acumenresearchandconsulting.com/buy-now/0/1769

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Contact Us:

Saurabh S.

Email: [email protected]

Phone: +14079154157 | +14089009135

Website: www.acumenresearchandconsulting.com

Source: pharmanewsdesk.com

Follow Us: LinkedIN | Twitter





Source link